Activins and BMPs: The yin and yang of diffuse midline gliomas.

A patient-derived brainstem glioma organoid platform reveals Activin B-ACVR2A signaling promotes DMG growth and suggests a triple intrathecal therapy for inhibition.

• Why it matters: Understanding tumor biology and developing effective treatments for diffuse midline gliomas (DMGs) is difficult due to limited models. Identifying key signaling pathways can guide targeted therapies.
• What they did: Xie et al. created a robust patient-derived brainstem glioma organoid (BSGO) platform and investigated signaling pathways, focusing on Activin B-ACVR2A, which was found to promote DMG growth, and tested a triple intrathecal therapy to inhibit this pathway.
• The result: The study highlights Activin B-ACVR2A as a promoter of DMG growth and proposes a promising therapeutic approach, advancing potential targeted treatments for this challenging tumor type.